STAAR Surgical Co. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 3, 2026. STAAR Surgical Co. designs, develops, manufactures, and sells implantable lenses (ICLs) for refractive surgery. The company operates as a single segment focused on ophthalmic surgical products. The reporting period reflects a strategic shift following the termination of a proposed merger with Alcon and the entry into a Cooperation Agreement with Broadwood Partners.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $93.5 million | $42.6 million |
| Gross Profit | $68.9 million | $28.0 million |
| Gross Margin | 73.6% | 65.8% |
| Operating Income | $8.0 million | $(57.4) million |
| Net Income | $5.2 million | $(54.2) million |
| Diluted EPS | $0.10 | $(1.10) |
| Cash & Cash Equivalents | $131.9 million | $173.1 million |
| Working Capital | $251.4 million | $243.0 million |
Liquidity & Debt: The company holds $163.9 million in cash and investments available for sale. There is no long-term debt reported; liabilities consist primarily of operating lease obligations ($37.3 million total) and accounts payable.
Material Changes vs. Prior Period
- Revenue Surge: Net sales increased 119.6% year-over-year, driven primarily by a 218% increase in the Asia Pacific region. China sales rebounded to $47.4 million from net returns of $0.9 million in the prior year, aided by the launch of the premium EVO+ ICL.
- Profitability Turnaround: The company returned to profitability with $5.2 million in net income, reversing a $54.2 million loss in Q1 2025. This was driven by higher gross margins and significantly reduced restructuring charges.
- Expense Reduction: Restructuring, impairment, and related charges dropped 88.2% to $2.7 million from $22.7 million in the prior year. General and administrative expenses decreased 30.4% due to cost reduction initiatives.
- Merger Costs: The company incurred $6.7 million in merger transaction and related costs in Q1 2026, primarily related to the termination of the Alcon merger and the Cooperation Agreement with Broadwood.
Outlook, Risks, and Management Commentary
- Manufacturing Strategy: Management expects to manufacture and supply 100% of EVO and EVO+ ICL lenses for China from its Swiss facility by the end of fiscal 2026, eliminating exposure to tariffs.
- Cash Flow: Operating cash flow was negative $21.7 million, primarily due to a $31.9 million increase in accounts receivable resulting from higher sales volume. Management expects to generate cash for the remainder of the year.
- Risks: Key risks include reliance on independent distributors (China distributors accounted for 51% of net sales), potential disruptions in the Chinese economy, foreign currency fluctuations, and regulatory approvals for new products.
- Leadership: The company completed a leadership realignment in Q1 2026, incurring severance costs of $1.6 million.
Investor Verification Checklist
- China Concentration: Verify the sustainability of the 51% revenue concentration in China and the success of the tariff mitigation strategy via Swiss manufacturing.
- Receivables Quality: Monitor the $81.2 million accounts receivable balance, noting that China distributors represent 57% of this total as of April 3, 2026.
- Merger Costs: Confirm that the $6.7 million in merger-related costs are one-time expenses and do not signal further transactional volatility.
- Inventory Levels: Assess the $49.8 million inventory balance, specifically the $7.1 million in consigned inventory, to ensure it aligns with actual procedure volumes.
- Operating Cash Flow: Track the conversion of net income to operating cash flow in subsequent quarters to ensure the receivable buildup is temporary.